Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01280669
Recruitment Status : Recruiting
First Posted : January 21, 2011
Last Update Posted : March 17, 2020
Sponsor:
Collaborator:
Santen Inc.
Information provided by (Responsible Party):
Quan Dong Nguyen, Stanford University

Tracking Information
First Submitted Date  ICMJE January 20, 2011
First Posted Date  ICMJE January 21, 2011
Last Update Posted Date March 17, 2020
Study Start Date  ICMJE March 2011
Estimated Primary Completion Date May 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 20, 2011)
Frequency of uveitic attacks as assessed by vitreous haze and cells. [ Time Frame: 6 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 20, 2011)
  • Incidence of adverse and serious adverse events [ Time Frame: 6 months ]
    Incidence, frequencey, and severity of adverse events reported during the first 6 months of the study period.
  • Changes in central retinal thickness [ Time Frame: 6 months ]
    Improvement or worsening of macular edema compared to baseline. Development of macular edema in patients with otherwise normal macualr thickness at baseline
  • Steroid sparing effect [ Time Frame: 6 months ]
    Proportion of subjects with active uveitis who achieve complete or partial response to sirolimus at month 6 while discontinuing their steroid therapy. Proportion of subjects with inactive uveitis who maintain quiscent study eyes at month 6 while discontinuing their steroid therapy.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Intravitreal Sirolimus as Therapeutic Approach to Uveitis
Official Title  ICMJE Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis
Brief Summary The purpose of this study is to find out about the safety and effectiveness of two different doses the study drug, sirolimus, administered intravitreally in patients with uveitis. The potential effectiveness of sirolimus can be utilized to control inflammation in uveitis and yet avoid the potential complications that are usually associated with the systemic use of the drug and other immunomodulatory therapies. In this study, the investigators will administer sirolimus inside the eye (intravitreally) in one of two doses (440mcg/mcL or 880mcg/mcL). Local administration of sirolimus to the eye is not expected to have effects on the rest of the body. Therefore, it may offer a safer way than the current methods used to control the inflammation caused by non-infectious uveitis.
Detailed Description

Uveitis is a condition in which certain parts of your eye become inflamed. The inflammation is usually recurrent. If the inflammation is not treated adequately, permanent damage to the eye and to the vision may occur. The inflammation can be caused by infectious or non infectious causes. The current research is being done to determine the safety and the usefulness of treatment of non-infectious uveitis using different doses of intravitreal injections of a drug called sirolimus.

Current treatment options for uveitis include oral corticosteroids and drugs that weaken the immune system of the body (i.e., immunosuppressant drugs). Treatment using oral corticosteroids, especially for long periods, may cause many undesirable side effects and complications such as high blood sugar, high blood pressure, bone weakness, obesity, stomach ulcers, abnormal hair growth, and increased risks of infection. In addition to that, in some cases, the disease cannot be controlled even with the highest dose of steroids.

Injection of steroids around and inside the eye can be used to control uveitis. However, the inflammation does not always respond to such kind of treatment. The eyes may develop high pressure and cataract with injections of steroids into the eyes or around the eyes.

On the other hand, despite their potential effectiveness, treatment with drugs that weaken the immune system may cause severe side effects. Increased risk of infection is a common side effect of all the immunosuppressant drugs. The immune system protects the body from infections. When the immune system is suppressed, infections are more likely to happen. Some of these infections are potentially dangerous. Because the immune system protects the body against some forms of cancer, immunosuppressant drugs are also associated with a slightly increased risk of cancer. For example, long-term use of immunosuppressant drugs may carry an increased risk of developing skin cancer as a result of the combination of the drugs and exposure to sunlight. The immunosuppressive drugs are very powerful and can cause serious side effects such as high blood pressure, kidney problems, and liver problems. Some side effects may not show up until years after the medicine is used.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Uveitis
  • Intermediate Uveitis
  • Posterior Uveitis
  • Panuveitis
Intervention  ICMJE
  • Drug: Intravitreal injection 440mcg
    Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
    Other Names:
    • Low-dose
    • Monthly
  • Drug: Intravitreal injection of sirolimus 880mcg
    Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
    Other Names:
    • High-dose
    • Bi-monthly
Study Arms  ICMJE
  • Experimental: Group 1
    Intravitreal injections of 440mcg sirolimus (low-dose monthly group)
    Intervention: Drug: Intravitreal injection 440mcg
  • Experimental: Group 2
    Intravitreal injections of 880mcg sirolimus (high-dose every other month group)
    Intervention: Drug: Intravitreal injection of sirolimus 880mcg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 20, 2011)
30
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2021
Estimated Primary Completion Date May 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males and females greater than or equal to 12 years of age.
  2. Able to give informed consent and attend all study visits.
  3. Have diagnosis of uveitis determined by the Investigator to be non-infectious based on the patient's medical history, history of present illness, ocular examination, review of systems, physical examination, and any pertinent laboratory evaluations.
  4. Meet the following criteria:

    • Have active uveitis, defined as having at least 1+ Vitreous Haze and/or at least 1+ Vitreous Cell Count (SUN scale), and:
    • are receiving no treatment; or
    • are receiving:

      • prednisone ≥ 10 mg/day (or equivalent dose of another corticosteroid), or
      • at least 1 systemic immunosuppressant other than corticosteroids, or
      • combination of prednisone ≥ 10 mg/day (or equivalent dose of another corticosteroid) and other systemic immunosuppressant.
    • Have inactive disease, defined as having 0.5+ Vitreous Haze or less and 0.5+ or less Vitreous Cell Count (SUN scale), and:
    • are receiving:

      • prednisone <10 mg/day (or equivalent dose of another corticosteroid), or
      • at least 1 systemic immunosuppressant other than corticosteroids, or
      • combination of prednisone <10 mg/day (or equivalent dose of another corticosteroid) and other systemic immunosuppressant.
    • Have posterior, intermediate, or panuveitis; for panuveitis, if an anterior component is present, it must be less than the posterior component.
    • Sufficient inflammation to require systemic treatment and, based on the Investigator's decision, warrants intravitreal treatment.
    • Best-corrected ETDRS visual acuity of 20/400 or better (approximately 20 letters) in the study eye.
    • Best-corrected ETDRS visual acuity of 20/400 or better in the fellow eye (approximately 20 letters).

Exclusion Criteria:

  1. Patients with bilateral uveitis who are receiving systemic immunosuppressive therapy (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate mofetil, tacrolimus, or azathioprine) other than prednisone or other corticosteroids for the treatment of uveitis and the uveitis in the fellow eye, in the opinion of the Investigator, cannot be controlled with standard local therapies alone;
  2. Any significant ocular disease that could compromise the visual outcome in the study eye.
  3. Intravitreal injections (including but not limited to anti-vascular endothelial growth factors 60 days prior to the baseline;
  4. Posterior subtenon's or intravitreal injection of steroids 90 days prior to Baseline;
  5. Intraocular surgery within 90 days prior to Day 0 in the study eye;
  6. Capsulotomy within 30 days prior to Day 0 in the study eye;
  7. History of vitreoretinal surgery or scleral buckling within 90 days prior to Day 0 in the study eye;
  8. Any ocular surgery (including cataract extraction or capsulotomy) of the study eye anticipated within the first 180 days following Day 0;
  9. Intraocular pressure ≥25 mmHg in the study eye (glaucoma patients maintained on no more than 2 topical medications with IOP <25 mmHg are allowed to participate);
  10. Pupillary dilation inadequate for quality fundus photography in the study eye;
  11. Media opacity that would limit clinical visualization, intravenous fluorescein angiography (IVFA), or OCT evaluation in the study eye;
  12. Presence of any form of ocular malignancy in the study eye, including choroidal melanoma;
  13. History of herpetic infection in the study eye or adnexa;
  14. Presence of known active or inactive toxoplasmosis in either eye;
  15. Ocular or periocular infection in either eye;
  16. Participation in other investigational drug or device clinical trials within 30 days prior to Day 0, or planning to participate in other investigational drug or device clinical trials within 180 days following Day 0. This includes both ocular and non-ocular clinical trials.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Quan D Nguyen, MD, MSc 6507244280 ndquan@stanford.edu
Contact: Lisa c Greer, MBA 6507259184 lgreer7@stanford.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01280669
Other Study ID Numbers  ICMJE NA_00046190
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Quan Dong Nguyen, Stanford University
Study Sponsor  ICMJE Stanford University
Collaborators  ICMJE Santen Inc.
Investigators  ICMJE
Principal Investigator: Quan D Nguyen, MD, MSc Stanford University Byers Eye Institute
PRS Account Stanford University
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP